Navigation Links
Epic Sciences Announces Series C Financing to Advance Essential Cancer Diagnostics for Personalized Medicine
Date:7/30/2014

SAN DIEGO, July 30, 2014 /PRNewswire/ -- Epic Sciences, Inc. ("Epic"), a privately held biotech company that designs and develops novel diagnostics to personalize and advance the treatment and management of cancer, announced today the completion of a $30 million Series C Preferred Stock financing. The financing included new investors RusnanoMedInvest (RMI) and Arcus Ventures, existing investors Domain Associates, Roche Venture Fund, and Pfizer Venture Investments, as well as undisclosed individual investors. With the proceeds of the financing, Epic will commercialize its circulating rare cell analysis platform with special focus on developing products and services to detect circulating tumor cells (CTC) in cancer. Epic's technology enables the rapid and minimally invasive characterization of protein biomarker and genomic profiles in CTCs allowing for superior therapy selection and the early drug resistance detection.

"Since our investment in the Series B, Epic has consistently expanded its commercial partnerships to develop new companion diagnostics, demonstrated the clinical utility of Epic's technology across a broad range of cancers, extended the capabilities of the core technology platform and attracted top talent to thoughtfully advance the company," said Kim Kamdar, Ph.D., partner at Domain Associates. "Domain Associates was enthusiastic to expand the investment and establish Epic as a premier provider of minimally invasive diagnostic tests to improve the precision of cancer care."

"With our partners, we have shown that Epic's CTC technology is sensitive, specific, and clinically relevant. We believe diagnostic tests developed with Epic technology will provide essential, real-time information to support a comprehensive view of a patient's cancer for better therapy matching and drug resistance monitoring," said Murali Prahalad, Ph.D., president and CEO of Epic Sciences. "We are grateful for the support of our new and returning top-tier investors. With the proceeds from the financing, Epic will enhance its technology via automation and advance multiple clinical studies for 510(k) fillings. The Epic team is focused on accelerating our diagnostic products through commercialization to ensure the best outcomes for patients."

Epic is developing highly sensitive and informative diagnostic tests to rapidly quantify the proteomic and genomic changes that occur over time during the treatment of a patient's cancer, from a minimally invasive liquid biopsy. With a simple blood draw, Epic's "no cell left behind" approach analyzes approximately six million cells across more than 90 parameters to capture and analyze all possible types of CTCs. CTCs are the most advanced blood-based biomarkers that can encompass the real-time genetic and molecular profiles of both primary tumors and metastases. For clinical and pharma partners, Epic provides a report that can incorporate CTC enumeration, quantitative protein biomarker analysis and single-cell genomic analysis by next generation sequencing (NGS) or fluorescent in situ hybridization (FISH). The information provided by Epic's report can be used to monitor and personalize cancer treatments at every clinical decision point.

Epic's technology was exclusively licensed from the Kuhn Lab at The Scripps Research Institute. "Epic's technology has achieved an unprecedented level of sensitivity in detecting circulating tumor cells to develop crucial cancer diagnostics for the millions of patients who need better ways to match drugs to their disease subtype and to understand whether their treatment is working," said Dr. Peter Kuhn, professor of Biological Sciences at the University of Southern California and co-founder of Epic. "In the near future, we will be able to answer the questions that doctors and patients have: what is the status of the cancer, what therapy can best treat the cancer and is that therapy working?"

About Epic Sciences

Epic Sciences, Inc. is developing novel diagnostics to personalize and advance the treatment and management of cancer. Epic's mission is to enable the rapid and non-invasive detection of genetic and molecular changes in cancer throughout a patient's journey. The company was founded on a powerful platform to identify and characterize rare cells, including CTCs. Our technology helps match patients to targeted therapies and monitor for drug resistance, so that the best treatment path can be chosen at every clinical decision point. Today, we partner with leading pharmaceutical companies and major cancer centers around the world. Epic's goal is to commercialize our technology to increase the success rate of cancer drugs in clinical trials and improve patient outcomes by providing physicians real-time information to guide treatment choices.

Further information is available on the Company's website, www.epicsciences.com. Stay in touch on Twitter @EpicSciences or on Facebook.com/EpicSciences.


'/>"/>
SOURCE Epic Sciences, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Regado Biosciences to Provide Second Quarter 2014 Financial Results and Corporate Highlights
2. Edwards Lifesciences Reports Strong Second Quarter Results
3. Neurocrine Biosciences Announces Conference Call And Webcast To Report Second Quarter 2014 Financial Results
4. Ambit Biosciences To Announce Second Quarter 2014 Financial Results
5. GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois
6. Healthcare Sciences Publisher PLM and IBM Speed Access to Medical Information to Deliver Better Patient Care with Mobile
7. Alimera Sciences To Release Second Quarter 2014 Results
8. The Medicines Patent Pool (MPP) Broadens Collaboration with Gilead Sciences: Signs Licence for Phase III Medicine Tenofovir Alafenamide (TAF)
9. Particle Sciences and Eyeon Therapeutics Receive Patent on Novel Dry Eye Technology
10. BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors
11. Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics Targeted Next Generation Sequencing Testing Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... , April 28, 2016  While Abbott,s ... complement the company,s valve repair and stent business, ... also places Abbott more firmly into patient monitoring.  ... the fastest growing device areas, with double-digit growth ... recent report,  Advanced Remote Patient Monitoring ...
(Date:4/28/2016)... Research and Markets has announced the addition ... report to their offering.      (Logo: ... plastic surgery products market is expected to grow at ... ,The growing adoption of laser in aesthetics is another ... Lasers are used to treat a broad range of ...
(Date:4/28/2016)... April 28, 2016  Marking its one year ... and ovarian cancer risk test, Color Genomics ... genes that highly impact the most common hereditary ... the Color Test analyzes hereditary cancer risks for ... uterine cancers. The Color Test is physician ordered ...
Breaking Medicine Technology:
(Date:4/28/2016)... ... ... Card reminds us that May is National Stroke Awareness Month. According to the Centers ... in the United States; someone has one every 40 seconds. Annually, almost 800,000 strokes ... old. A stroke is when blood flow to the brain is blocked or when ...
(Date:4/28/2016)... ... April 28, 2016 , ... Point ... miniature microphones and headsets announced today that the US Patent Office has approved ... into a structure. This innovative design creates a lightweight and modular audio headset ...
(Date:4/28/2016)... ... April 28, 2016 , ... Accreditation Commission for ... Pharmacy Association (COPA) to develop a comprehensive Specialty Pharmacy Accreditation with Distinction in ... accreditation distinction. ACHC provides a wide range of pharmacy accreditation services that assess ...
(Date:4/28/2016)... ... April 28, 2016 , ... Starting today, households ... mail from USA Medical Prescription Assistance Program. They are customized to reflect the ... package will include a ready-to-use, state-themed card and, in the near future, material ...
(Date:4/28/2016)... (PRWEB) , ... April 28, 2016 , ... For the ... means getting smarter about an important part of overall well-being: mental health. Now, a ... do to promote healthy aging and “cognitive vitality,” which can include everything from honing ...
Breaking Medicine News(10 mins):